Health Care·Biotechnology·$3.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about their clinical developments. They are focused on long-term goals while navigating current financial challenges.
Management highlighted ongoing progress in their clinical trials.
They emphasized a commitment to advancing their pipeline despite current losses.
Denali Therapeutics reported a loss per share of $0.41, with no revenue figures disclosed. Despite the EPS miss, the stock saw a slight increase of 0.13%, likely driven by positive sentiment around their ongoing clinical trials and management's optimistic outlook. Investors may be encouraged by the company's focus on long-term growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019